Finn
ZLAB Biopharma · China biotech · Commercial stage · Oncology · Thesis updated November 8, 2026

Pivoting globally as local pricing pressures persist

01 Running thesis

A global reset after local setbacks

Zai Lab is navigating a transition period. The company reported a 2 percent sequential increase in net product revenue during the third quarter of 2026, signaling stabilization in its China commercial business. While its top drug, ZEJULA, faced intense pressure earlier in the year from generic competition, the broader portfolio is beginning to offset the damage. Newer products and a recent 250 million dollar equity raise provide a bridge to the future.

To counter local pricing pressure, the company points to its diversified portfolio and a strategic pivot toward global markets. Early data for Zoci, an antibody drug conjugate for small cell lung cancer, showed a highly compelling 81.8 percent objective response rate. Management has outlined concrete 2027 milestones for Zoci, including potential U.S. regulatory submissions for accelerated approval. This global ambition could significantly alter the valuation of the company if successful.

The bear case remains focused on immediate commercial hurdles. The rapid erosion of ZEJULA sales removes a primary profit engine just as the company needs capital for global trials. XACDURO is growing, but severe supply constraints limit its contribution until local manufacturing comes online. Furthermore, China reimbursement rules impose strict price controls, making near term profitability harder to achieve.

Finn scores reflect a cautious view. Growth and sentiment hold promise based on the pipeline, but low valuation and performance scores show the market requires proof that new products can outpace the decay of older ones. The critical tests ahead are the easing of XACDURO supply issues and the timely progress of Zoci clinical trials.

Nov 2026▲Q3 2026 results showed stabilization with a 2 percent sequential product revenue increase. Zoci presented strong Phase I data and the company raised 250 million dollars in equity.
Aug 2026→Q2 2026 results showed a 3 percent product revenue decline as ZEJULA and VYVGART faced pricing headwinds. TIVDAK was approved and KarXT launched in China.
May 2026▼Q1 2026 showed a 10 percent revenue drop as ZEJULA fell 39 percent. Management guided for continued revenue pressure in 2026 before a return to growth in 2027.
Feb 2026→The 2025 10-K showed full year revenue growth and a smaller net loss, plus KarXT approval. It also brought back the ZEJULA sales investigation as a serious legal and reputation risk.
Nov 2025▲Q3 2025 revenue grew 13 percent, and net loss narrowed to $36.0 million. The view improved because NUZYRA and XACDURO helped offset softer ZEJULA sales.
Aug 2025▼Q2 2025 showed revenue growth slowing to 9 percent as ZEJULA fell 9 percent. Cost control helped losses narrow, but the main product risk became harder to ignore.
May 2025▲Q1 2025 revenue rose 21 percent, helped by NUZYRA, VYVGART, and ZEJULA. XACDURO and AUGTYRO added early diversification, while ZL-1102 was discontinued.
Feb 2025▲The 2024 10-K showed revenue up 50 percent and a much smaller net loss, led by VYVGART. The same filing added a new ZEJULA sales investigation risk.
02 Business model

License locally, develop globally

Historically, Zai Lab has operated by licensing promising clinical stage drugs from global pharmaceutical companies. The company runs the necessary local trials, secures regulatory approval from Chinese authorities, and builds the commercial infrastructure to sell the drugs in Greater China. This model allowed Zai Lab to build a broad portfolio quickly without the extreme early stage risks of pure drug discovery.

Revenue generation is highly dependent on securing a spot on the National Reimbursement Drug List in China. Being on the list dramatically increases the number of patients who can afford a drug, but it almost always requires the manufacturer to accept severe price cuts. Balancing this volume for price tradeoff is central to the financial health of the company. Recent price adjustments for key products illustrate this constant pressure.

The business is now evolving. Instead of relying solely on the Chinese market, Zai Lab is investing heavily in global clinical trials for its own innovative assets. Developing drugs for a worldwide market requires significantly more capital but offers far larger revenue potential and escapes the specific pricing constraints of the Chinese healthcare system. Proving they can successfully execute a regulatory submission in the United States is the next major hurdle.

03 Product portfolio

A shifting revenue mix

Cash cow

ZEJULA

A PARP inhibitor for ovarian cancer maintenance. Once the growth engine, sales have fallen due to generic competition in China.

Steady

VYVGART

Treatments for generalized myasthenia gravis and CIDP. Revenue has faced pressure from a recent price adjustment related to reimbursement renewal.

Steady

NUZYRA

An antibiotic for community-acquired pneumonia and skin infections. It provides a stable portion of total product revenue.

Growth engine

XACDURO

An antibiotic for specific hospital-acquired pneumonias. Demand is growing rapidly, but actual sales are currently capped by supply limitations.

Option

KarXT

A newly launched treatment for adult schizophrenia. Its commercial uptake will be crucial for returning the company to growth in 2027.

Option

Zoci

An internally developed antibody drug conjugate for small cell lung cancer. It represents the primary global oncology bet for the company.

04 Business segments

Product mix

ZEJULA31%declining
VYVGART and VYVGART Hytrulo18%flat
NUZYRA17%modest
OPTUNE13%flat
QINLOCK9%flat
XACDURO9%growing fast
AUGTYRO and other2%modest

Zai Lab operates as a single segment. Based on 2026 data, the revenue base remains highly concentrated, with ZEJULA historically accounting for roughly a third of total product sales.

05 Risk factors

What could go wrong

ZEJULA collapse

High impact · High odds

The sharp drop in early 2026 ZEJULA sales shows severe vulnerability to generic olaparib. If hospital utilization patterns in China permanently shift away from ZEJULA, the company will lose its largest source of cash before its global pipeline matures.

We watchQuarterly ZEJULA revenue trends and commentary on the competitive PARP inhibitor market.

XACDURO supply failure

Medium impact · High odds

Management has stated that strong underlying demand for XACDURO is being artificially constrained by supply shortages. If local manufacturing efforts fail to resolve this by early 2027, the company will miss a critical window to offset other revenue declines.

We watchUpdates on XACDURO supply chain capacity and local manufacturing timelines.

Zoci trial setbacks

High impact · Medium odds

The entire global pivot rests heavily on Zoci. While early data in small cell lung cancer showed promise, antibody drug conjugates frequently face unexpected safety signals or fading efficacy in larger clinical trials. A failure here damages the long term thesis.

We watchPhase III enrollment progress in early 2027 and any reported severe adverse events.

China reimbursement pricing

High impact · High odds

The Chinese healthcare system uses its National Reimbursement Drug List to force massive price concessions from drugmakers. Recent cuts prove this risk is ongoing, meaning higher prescription volumes do not guarantee revenue growth.

We watchFuture reimbursement inclusion outcomes and the resulting price adjustments for key products.

Legacy legal overhang

Medium impact · Medium odds

Chinese authorities are conducting a criminal investigation into current and former ZEJULA sales employees regarding alleged medical insurance fraud. This creates a lingering reputational risk and potential operational disruption for the commercial team.

We watchFilings for updates on the investigation or any formal charges against the company.
06 Quick answers

In one breath

What is Zai Lab's business model?

Zai Lab historically licensed drugs from overseas to sell in Greater China. It is now expanding to develop its own oncology drugs for the global market.

Why are Zai Lab sales dropping?

Total revenue fell in early 2026 primarily because its top drug, ZEJULA, faced intense generic competition. VYVGART also faced price adjustments.

What is the upside for ZLAB stock?

If new launches like KarXT and XACDURO scale quickly, and if the global oncology drug Zoci secures approval in the United States by 2028, the valuation could expand significantly.

What are the biggest risks for ZLAB?

The biggest risks are the continued collapse of ZEJULA revenues, ongoing supply constraints for growth products, and the uncertainty of large global clinical trials.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Zai Lab Q2 2026 Form 10-Q
  2. Zai Lab Q3 2026 Earnings Transcript
08 Explore the industry

Comparable Biotechnology companies

Companies near Zai Lab Limited in Finn's Biotechnology industry ranking.

Get started with Finn today